Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2016
At a glance
- Drugs ONT 10 (Primary)
- Indications Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Cascadian Therapeutics
- 16 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 03 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 09 May 2014 Planned End Date changed from 1 Jun 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov record.